Correlation Between INGERSOLL and Apogee Therapeutics,

Can any of the company-specific risk be diversified away by investing in both INGERSOLL and Apogee Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining INGERSOLL and Apogee Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between INGERSOLL RAND LUXEMBOURG FIN and Apogee Therapeutics, Common, you can compare the effects of market volatilities on INGERSOLL and Apogee Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in INGERSOLL with a short position of Apogee Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of INGERSOLL and Apogee Therapeutics,.

Diversification Opportunities for INGERSOLL and Apogee Therapeutics,

-0.52

Correlation Coefficient

INGERSOLL  Apogee Therapeutics,

Excellent diversification

The 3 months correlation between INGERSOLL and Apogee is -0.52. Overlapping area represents the amount of risk that can be diversified away by holding INGERSOLL RAND LUXEMBOURG FIN and Apogee Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apogee Therapeutics, and INGERSOLL is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on INGERSOLL RAND LUXEMBOURG FIN are associated (or correlated) with Apogee Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apogee Therapeutics, has no effect on the direction of INGERSOLL i.e., INGERSOLL and Apogee Therapeutics, go up and down completely randomly.

Pair Corralation between INGERSOLL and Apogee Therapeutics,

Assuming the 90 days trading horizon INGERSOLL RAND LUXEMBOURG FIN is expected to under-perform the Apogee Therapeutics,. But the bond apears to be less risky and, when comparing its historical volatility, INGERSOLL RAND LUXEMBOURG FIN is 2.2 times less risky than Apogee Therapeutics,. The bond trades about -0.19 of its potential returns per unit of risk. The Apogee Therapeutics, Common is currently generating about 0.13 of returns per unit of risk over similar time horizon. If you would invest  4,286  in Apogee Therapeutics, Common on September 22, 2024 and sell it today you would earn a total of  485.00  from holding Apogee Therapeutics, Common or generate 11.32% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	28.57%
Values	Daily Returns

INGERSOLL RAND LUXEMBOURG FIN  vs.  Apogee Therapeutics, Common

INGERSOLL RAND LUXEM

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days INGERSOLL RAND LUXEMBOURG FIN has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Bond's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for INGERSOLL RAND LUXEMBOURG FIN investors.

Apogee Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Apogee Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with INGERSOLL and Apogee Therapeutics,

The main advantage of trading using opposite INGERSOLL and Apogee Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if INGERSOLL position performs unexpectedly, Apogee Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apogee Therapeutics, will offset losses from the drop in Apogee Therapeutics,'s long position.

The idea behind INGERSOLL RAND LUXEMBOURG FIN and Apogee Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.